Defunct Company
Total Trials
8
As Lead Sponsor
4
As Collaborator
Total Enrollment
248
NCT00805376
DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 28, 2009
Completion: Feb 28, 2015
NCT01956734
Virus DNX2401 and Temozolomide in Recurrent Glioblastoma
Role: Collaborator
Start: Sep 30, 2013
Completion: Mar 31, 2017
NCT02197169
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Start: Sep 11, 2014
Completion: Mar 15, 2018
NCT02798406
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Phase: Phase 2
Start: Oct 6, 2016
Completion: Jun 30, 2021
NCT03178032
Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas
Start: May 26, 2017
Completion: Jan 31, 2021
NCT03714334
DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
Start: Oct 16, 2018
Completion: Apr 5, 2023
NCT03896568
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Start: Feb 12, 2019
Completion: Sep 30, 2027
NCT04714983
DNX-2440 for Resectable Colorectal Liver Metastasis
Start: Feb 15, 2021
Completion: Dec 31, 2026